COPENHAGEN, Denmark, Sept. 22 /PRNewswire/ -- Genmab A/S (CSE: GEN) announced today it has completed enrollment in the HuMax-CD20(TM) (ofatumumab) Phase II study to treat patients with active rheumatoid arthritis (RA) who have failed treatment with one or more disease modifying anti-rheumatic drugs (DMARDs) including biologics. A total of approximately 200 patients have been enrolled in the study.
“Genmab’s clinical development team has worked diligently to ensure rapid enrollment of patients in this RA study and we are looking forward to seeing results,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer at Genmab.
About HuMax-CD20 (ofatumumab)
HuMax-CD20 is a human antibody which is effective at binding to the CD20 molecule on B-cells. Results from the Phase I/II study to treat patients with active RA showing that 73% of patients treated with two doses of HuMax-CD20 achieved ACR20, 38% achieved ACR50 and 15% achieved ACR70 were presented in March 2006.
Two pivotal studies in HuMax-CD20 to treat chronic lymphocytic leukemia and follicular non-Hodgkin’s lymphoma are ongoing.
About Genmab A/S
Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche, Amgen and Serono. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb(R) platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab has operations in Copenhagen, Denmark, Utrecht, the Netherlands, Princeton, New Jersey, US and Hertfordshire in the United Kingdom. For more information about Genmab, visit www.genmab.com.
This press release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-CD20(TM); HuMax-TAC(TM); HuMax-HepC(TM) and HuMax-CD38(TM) are all trademarks of Genmab A/S. UltiMAb(R) is a trademark of Medarex, Inc.
Genmab A/S
CONTACT: Helle Husted, Director, Investor Relations of Genmab A/S, +45 3344 77 30, or mobile, +45 25 27 47 13, or hth@genmab.com
Web site: http://www.genmab.com//
